Erytech Pharma S.A. (ERYP): Price and Financial Metrics
ERYP Price/Volume Stats
| Current price | $0.78 | 52-week high | $1.47 |
| Prev. close | $0.78 | 52-week low | $0.30 |
| Day low | $0.78 | Volume | 3,200 |
| Day high | $0.88 | Avg. volume | 93,510 |
| 50-day MA | $0.88 | Dividend yield | N/A |
| 200-day MA | $0.74 | Market Cap | 26.61M |
ERYP Stock Price Chart Interactive Chart >
Erytech Pharma S.A. (ERYP) Company Bio
ERYTECH Pharma Société Anonyme, a clinical-stage biopharmaceutical company, develops therapies for rare forms of cancer and orphan diseases in France and internationally. The company is developing a pipeline of product candidates targeting markets with unmet medical need using its proprietary ERYCAPS platform, a technology to encapsulate therapeutic drug substances inside red blood cells. It primarily focuses on the treatment of blood cancers, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), by depriving tumors of nutrients necessary for their survival. The company was founded in 2004 and is based in Lyon, France.
Latest ERYP News From Around the Web
Below are the latest news stories about ERYTECH PHARMA SA that investors may wish to consider to help them evaluate ERYP as an investment opportunity.
ERYTECH announces that the Commercial Court has rejected Akkadian's request to postpone the vote on the merger with Pherecydes PharmaERYTECH announces that the Commercial Court has rejected Akkadian's request to postpone the vote on the merger with Pherecydes Pharma Cambridge, MA (U.S.) and Lyon (France), June 14, 2023, 8:00 pm CEST – ERYTECH Pharma (Nasdaq & Euronext: ERYP), announced today that the Lyon Commercial Court has rejected Akkadian's request to postpone the vote on the merger with Pherecydes Pharma. Erytech is pleased with today's order delivered by the President of the Lyon Commercial Court. This order rejected A |
Erytech's Battle With Activist Investor Echoes As Pherecydes Pharma Merger Vote Comes CloserIn February, Erytech Pharma SA (NASDAQ: ERYP) announced its proposed combination with Pherecydes Pharma S.A. In June, Erytech announced that Akkadian initiated proceedings to postpone the vote, scheduled on 23 June, on the merger with Pherecydes. The merger would see Pherecydes absorbed into publicly listed Erytech, with Pherecydes shareholders receiving 15 new Erytech shares for every four of their current shares. Monday, Erytech Pharma responded to what it described as Akkadian Partners' "disi |
Monthly information related to total number of voting rights and shares composing the share capital _May 31, 2023Monthly information related to total number of voting rights and shares composing the share capital _May 31, 2023. Article 223-16 of general regulation of French Autorité des Marchés FinanciersLyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)Website : www.erytech.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net (2) v |
ERYTECH Responds to Akkadian’s DisinformationERYTECH Responds to Akkadian’s Disinformation Akkadian’s challenge of the merger is based on incomplete information and misleading argumentsAkkadian has not presented any valuable alternative optionAkkadian’s unfounded actions present a risk of destruction of shareholder value and loss of employment at two companies, and the potential loss of a strategically important technology in FranceIn this context, ERYTECH reminds its shareholders of the importance of participating in the Annual General Me |
ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with PherecydesERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with Pherecydes Cambridge, MA (U.S.) and Lyon (France), June 5, 2023 – ERYTECH Pharma (Nasdaq & Euronext: a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Akkadian Partners has initiated legal proceedings to obtain the postponement of the vote on the merger with Pherecydes at the Annual Gen |
ERYP Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | -20.41% |
| 1-year | 44.23% |
| 3-year | -86.55% |
| 5-year | -90.90% |
| YTD | 136.29% |
| 2022 | -85.95% |
| 2021 | -74.54% |
| 2020 | 25.15% |
| 2019 | 8.94% |
| 2018 | -69.26% |
Continue Researching ERYP
Want to see what other sources are saying about Erytech Pharma SA's financials and stock price? Try the links below:Erytech Pharma SA (ERYP) Stock Price | Nasdaq
Erytech Pharma SA (ERYP) Stock Quote, History and News - Yahoo Finance
Erytech Pharma SA (ERYP) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...